• Hronn Harðardottir, Steinn Jonsson, Orvar Gunnarsson, Bylgja Hilmarsdottir, Jurate Asmundsson, Ingibjorg Gudmundsdottir, Vaka Yr Saevarsdottir, Sif Hansdottir, Petur Hannesson, and Tomas Gudbjartsson.
• Department of Respiratory Medicine, Landspitali University Hospital, Reykjavik, Iceland.
• Laeknabladid. 2022 Jan 1; 108 (1): 17-29.

AbstractLung cancer is the second and third most common cancer in Iceland for females and males, respectively. Although the incidence is declining, lung cancer still has the highest mortality of all cancers in Iceland. Symptoms of lung cancer can be specific and localized to the lungs, but more commonly they are unspecific and result in significant diagnostic delay. Therefore, majority of lung cancer patients are diagnosed with non-localized disease. In recent years, major developments have been made in the diagnosis and treatment of lung cancer. Positive emission scanning (PET) and both transbroncial (EBUS) or transesophageal ultrasound (EUS) biopsy techniques have resulted in improved mediastinal staging of the disease and minimal invasive video-assisted thoracic surgery (VATS) has lowered postoperative complications and shortened hospital stay. Technical developments in radiotherapy have benefitted those patients who are not candidates for curative surgery. Finally, and most importantly, recent advances in targeted chemotherapeutics and development of immunomodulating agents have made individual tailoring of treatment possible. Recent screening-trials with low-dose computed tomography show promising results in lowering mortality. This evidence-based review focuses on the most important developments in the diagnosis and treatment of lung cancer, and includes Icelandic studies in the field.

24 keywords...

hide…